Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Algernon Pharmaceuticals Inc C.AGN

Alternate Symbol(s):  AGNPF

Algernon Pharmaceuticals Inc. is a clinical-stage drug development company. The Company is focused on developing repurposed therapeutic drugs in the areas of non-alcoholic steatohepatitis (NASH), a type of liver disease, chronic kidney disease (CKD), inflammatory bowel disease (IBD), idiopathic pulmonary fibrosis (IPF) and chronic cough as well as advancing a stroke program using N, N-Dimethyltryptamine (DMT). The Company operates through two segments, which includes the development of repurposed therapeutic drugs in Canada and the facilitation of the Company’s lead drug candidates into off-label phase II clinical trials (humans) in Australia. The Company's pipeline includes NP-251 (Repirinast) and AP-188 (DMT). The Company, through its subsidiary, Algernon NeuroScience Inc., is developing AP-188 (DMT) as a potential treatment for stroke and traumatic brain injury (TBI) recovery. Its NP-251 is being developed as a potential treatment for kidney inflammation and fibrosis.


CSE:AGN - Post by User

Comment by NightHawk1987on May 22, 2020 6:29pm
117 Views
Post# 31063175

RE:RE:RE:RE:Trading below PP

RE:RE:RE:RE:Trading below PP Glad to see you back Algernon (or maybe AMG) and Danny. You two provide incredible insight. I, and others, are very appreciative. FULL disclosure... This is the longest I've held onto a bio pharma stock (been 4 weeks now I think. Lol at the last high point) usually I use abuse them. In and out. But I believe in Ifenprodyl. I only have 40k shares. Not the end all, be all. But, still a decent amount for me, maybe not others. I have learned a ton in the last 4 weeks about bio tech companies. Usually I make my hay in the tech and energy sectors. So this is uncharted territory for more, so to speak. Now, with that being said, this is where I want some True, Factual Feedback. Please tell me why....... -The US FDA IND has not been approved, applied or anything! Except "positive feedback." Algernon made a public NR stating they were starting this in March. They are the last leg of the international tripod, and the most important. The money, and the world rotates with the US. -The S Korea trials. Now, this one to me is more explainable. Maybe a NDA with Korea, or they haven't started yet because of lack of patients. (Which I have a hard time believing.) To me it's one of 2 things... there's an NDA or they jumped the gun on the start date, and weren't fully prepared, capable, lack of funding, partnership, etc. Not to mention, its Korea. Their rules, or your out. I have a feeling it's the latter. -Lack of insider investment. Now, from what I've read on here about the Kal drama...whatever. This is big boy business. Some sleaze ball grabbing a couple million isnt a big deal. I'm looking at big picture. So put your hurt feelings from Kal aside. Why isnt their more insider investment. And on the flip side, that explains the lack of F's given to timely NR's and share price. And if you disagree with one, then explain the other... Again, I am NOT bashing AGN. I am a holder. Just doing my DD. I really believe the share price should be at least .75 cents right now, and it would be if management gave a damn. If it was more public. Like you mentioned, we are leaps and bounds ahead of most. We are in phase 1 and 2 everywhere! I'm not looking for validation. I am not selling until I see Data. And with the slow pattern of the last month, I expect a NR next week, but I don't expect any value to come from it. There is nothing to show otherwise. Just my quick thoughts on my phone in between changing diapers. Please fill in the gaps. I know there are many. Have a great weekend.
<< Previous
Bullboard Posts
Next >>